Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Unity Software Inc (U) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Unity Software Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.9 (market cap $4.49B), while Unity Software Inc trades at $29.36 (market cap $12.95B). The key difference: Unity Software Inc is far larger — about 2.9× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Unity Software Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | U | |
|---|---|---|
Market Cap | $4.49B | $12.95B |
Sector | Health | Technology |
52-Week High | $28.06 | $49.47 |
52-Week Low | $20.06 | $17.13 |
Enterprise Value | $3.69B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Unity Software (U) trades at $29.66, up 1.16% today, with a bullish technical outlook and strong analyst support. The stock shows improving fundamentals with revenue stable at $1.85 billion in 2025 and narrowing losses, while operating cash flow grew to $423 million. Recent news highlights Unity's strategic pivot toward AI-driven advertising and developer tools, boosting investor confidence despite ongoing net losses.
The outlook is cautiously optimistic with a consensus price target of $36.50 implying 23% upside. Key opportunities include AI integration and margin expansion, but risks persist from competitive pressures, high debt, and profitability challenges. Investors should weigh growth potential against execution risks in the evolving tech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
